A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Summary

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Parkinson Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

30 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Appello Pharmaceuticals, Inc.

Last updated on ClinicalTrials.gov

October 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites